
Burcon NutraScience (TSE:BU) reported nearly threefold year-over-year revenue growth in its fiscal 2027 second quarter, even as production infrastructure problems contributed to a sequential sales decline. Management said it expects significant quarter-over-quarter growth in the third quarter and sees a path to positive cash flow during calendar 2027.
Chief Executive Officer Kip Underwood said the plant-protein company is investing in production capacity and reliability as it prepares for demand from food makers. He pointed to consumers using GLP-1 weight-loss medications as a potential source of growth for specialty proteins.
Revenue growth tempered by production issues
Interim Chief Financial Officer Alex Varty said the year-over-year revenue increase was driven predominantly by growing sales of Burcon’s protein offerings. Revenue fell 18% from the first quarter, however, reflecting the timing of late first-quarter shipments and the production ramp, including the need for additional infrastructure.
The loss from operations declined 2% sequentially despite the lower sales, Varty said, citing reductions in cost of sales and general and administrative expenses. He said production volumes accelerated after the quarter ended and that the company maintained a strong customer order book. The call did not provide dollar figures for quarterly revenue or the operating loss.
Underwood attributed the production challenges to infrastructure, including steam and water supplies, rather than Burcon’s protein technology. He said the company had addressed the issues and was seeing improvements in daily production and efficiency.
Burcon kept existing customers supplied but slowed efforts to bring on new ones during the disruption, Underwood said. The facility currently operates 24 hours a day, five days a week, and the company plans to move to a seven-day schedule in the coming months.
Financing and capacity plans
The loan from the Pekar-related entity matures in November 2027, Varty said. Its proceeds will provide working capital for ongoing operations and the production and sale of plant proteins.
Underwood said the loan would bridge the company while it pursues a broader financing raise, which he described as taking place in a difficult fundraising market. He said the funds also supported investments in infrastructure reliability, production capacity and staffing, and that the company expected to provide more information on the raise in the coming weeks.
For facility capacity investments, Underwood said operating partner RE ProMan, LLC provides capital that Burcon effectively leases back. The funds Burcon is raising are largely intended for staffing, facility reliability, working capital and inventory, he said.
Customer pipeline and 2027 outlook
Underwood said 26 of Burcon’s 209 active projects had progressed beyond the pallet-order stage and could drive growth in early to mid-2027. Customer projects typically take nine to 24 months to reach a food-product launch, he said.
The company is producing and selling pea, canola, fava and sunflower proteins, Underwood said. He argued that demand for protein-enhanced foods is expanding beyond sports nutrition into products such as cereals, pasta and oatmeal, creating an opportunity for Burcon’s ingredients.
Management sees a path to a revenue run rate above $10 million, operating leverage and positive cash flow during calendar 2027. Underwood said rising production could improve margins as sales grow against a largely established fixed-cost base. He also described a potential future licensing model once the company is financially stronger and its facility is operating near capacity.
About Burcon NutraScience (TSE:BU)
Burcon is a global technology leader in plant-based proteins for food and beverage applications. The Company has developed a portfolio of high-performance protein ingredients, including Peazzaz® pea proteins, FavaPro TM fava proteins and Puratein® canola proteins, and is focused on commercializing its technologies through manufacturing partnerships and growing customer adoption worldwide.
